Close Menu


News and reporting on melanoma.

In a survey, analysts found that reimbursement and test awareness were major barriers to driving adoption of the firm's assay for identifying skin cancer.

OncoHost will use the funding to finance clinical trials, open a US location, and prepare to launch its proteomics platform called Prophet.

In PLOS this week: genomic and transcriptomic analysis of conjunctival melanoma, phylogenetic analysis of Clostridioides difficile, and more.

Early data around an initial composite assay showed it can predict immunooncology drug responses more accurately than tumor mutational burden.

The investment bank highlighted the technology underlying DermTech's non-invasive, skin patch-based melanoma test as key to its future growth.

The group aims to determine the feasibility of TROLL-2 and TROLL-3 as diagnostic biomarkers for the prediction of treatment efficacy and prognosis in breast cancer.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

The company this month launched a lower priced benchtop instrument and a more versatile flagship product as well as a new intracellular protein assay.

The B44 supertype is associated with improved survival in melanoma patients treated with immunotherapy, but less so in NSCLC patients, due to mutational differences.

The skin cancer diagnostics company said it delivered 7 percent more DecisionDx-Melanoma test results in Q3 2020 than in the previous year's third quarter.


The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.